Relief Therapeutics Holding AG (RLFTF)

[mc67]

$RLFTF DD "opinion" Post by DanG on Ya-h00 - I would not usually post, especially twice in one day, but it appears necessary.

First, I spoke to Brian Korb in Investor Relations at NeuroRx about an hour ago, right before Zaran posted. Basically Brian told us both that there is no conference call and any significant news will come via a press release.

In terms of all the speculation on the board I can only offer observations, as there is no firm data yet.

My experience investing in bio stocks is that rumors and long waits can cause fluctuations in price often unrelated to real news. So let's look at what we do know:

Trial results will be released this month.

The inhaled trial has begun.

Hiring continues in both NeuroRx and Relief, as well as companies responsible for production and distribution of Aviptadil.

The primary stockholder, GEM, has provided the means to fund Relief into 2022.

The merger between NeuroRx and BRPA is proceeding.

All available evidence indicates Aviptadil is effective and safe.

Conclusion:
There are no sure things but the evidence suggests there is good reason for optimism